Use of Meningococcal Vaccines in the United States
- 1 May 2007
- journal article
- review article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 26 (5) , 371-376
- https://doi.org/10.1097/01.inf.0000259996.95965.ef
Abstract
In January 2005, Food and Drug Administration licensed a new tetravalent (serogroups A, C, Y, W-135) meningococcal conjugate vaccine ([MCV4] Menactra) for use in persons 11-55 years of age. In February 2005, CDC's Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination of adolescents and college freshmen living in dormitories with MCV4. The manufacturer started shipments of MCV4 in March 2005. MCV4 should become a key addition to existing meningococcal disease prevention measures.Keywords
This publication has 61 references indexed in Scilit:
- Risk Factors for Meningococcal Disease in College StudentsJAMA, 2001
- The Changing Epidemiology of Meningococcal Disease in the United States, 1992–1996The Journal of Infectious Diseases, 1999
- Meningococcal Disease in College StudentsClinical Infectious Diseases, 1999
- Risk of meningococcal infection in college students.JAMA, 1999
- Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodationEpidemiology and Infection, 1999
- Neisseria meningitidis serogroup B: Emergence of the ET-5 complexSeminars in Pediatric Infectious Diseases, 1997
- Pathophysiology, Treatment and Outcome of Meningococcemia: A Review and Recent ExperienceThe Pediatric Infectious Disease Journal, 1996
- Reactogenicity and Immunogenicity of a Quadrivalent Combined Meningococcal Polysaccharide Vaccine in ChildrenThe Journal of Infectious Diseases, 1986
- Complications and sequelae of meningococcalinfections in childrenThe Journal of Pediatrics, 1981
- Prevention of Meningococcal Disease by Group C Polysaccharide VaccineNew England Journal of Medicine, 1970